DK0614465T3 - Hybridprotein mellem CS fra Plasmodium og HBsAg - Google Patents
Hybridprotein mellem CS fra Plasmodium og HBsAgInfo
- Publication number
- DK0614465T3 DK0614465T3 DK92923486T DK92923486T DK0614465T3 DK 0614465 T3 DK0614465 T3 DK 0614465T3 DK 92923486 T DK92923486 T DK 92923486T DK 92923486 T DK92923486 T DK 92923486T DK 0614465 T3 DK0614465 T3 DK 0614465T3
- Authority
- DK
- Denmark
- Prior art keywords
- hbsag
- plasmodium
- hybrid protein
- protein
- falciparum
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 241000224016 Plasmodium Species 0.000 title 1
- 241000700721 Hepatitis B virus Species 0.000 abstract 1
- 241000223960 Plasmodium falciparum Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10123—Virus like particles [VLP]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB919124390A GB9124390D0 (en) | 1991-11-16 | 1991-11-16 | Vaccines |
US84269492A | 1992-02-27 | 1992-02-27 | |
PCT/EP1992/002591 WO1993010152A1 (en) | 1991-11-16 | 1992-11-11 | HYBRID PROTEIN BETWEEN CS FROM PLASMODIUM AND HBsAG |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0614465T3 true DK0614465T3 (da) | 1999-09-27 |
Family
ID=26299880
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK92923486T DK0614465T3 (da) | 1991-11-16 | 1992-11-11 | Hybridprotein mellem CS fra Plasmodium og HBsAg |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0614465B1 (de) |
JP (2) | JP3954643B2 (de) |
KR (1) | KR100251505B1 (de) |
AT (1) | ATE177755T1 (de) |
AU (2) | AU2927892A (de) |
CA (1) | CA2123612C (de) |
DE (1) | DE69228698T2 (de) |
DK (1) | DK0614465T3 (de) |
ES (1) | ES2129461T3 (de) |
GR (1) | GR3029717T3 (de) |
HK (1) | HK1012405A1 (de) |
MX (1) | MX9206574A (de) |
NZ (1) | NZ245114A (de) |
PT (1) | PT101052B (de) |
SG (1) | SG48390A1 (de) |
WO (1) | WO1993010152A1 (de) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6620414B2 (en) | 1992-03-27 | 2003-09-16 | Smithkline Beecham Biologicals (S.A.) | Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A |
SG49909A1 (en) | 1992-06-25 | 1998-06-15 | Smithkline Beecham Biolog | Vaccine composition containing adjuvants |
GB9616351D0 (en) * | 1996-08-02 | 1996-09-11 | Smithkline Beecham Biolog | Vaccine composition |
TR200101055T2 (tr) | 1998-10-16 | 2001-09-21 | Smithkline Beecham Biologicals S.A. | Adjuvan sistemler ve aşılar |
GB9915204D0 (en) * | 1999-06-29 | 1999-09-01 | Smithkline Beecham Biolog | Vaccine |
GB0109297D0 (en) | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
EP1569515A4 (de) | 2002-10-23 | 2006-04-26 | Glaxosmithkline Biolog Sa | Malaria-impfverfahren |
EP2258850B1 (de) | 2002-12-17 | 2013-07-17 | Crucell Holland B.V. | Rekombinanter virus-basierter malaria impfstoff |
AU2003244053A1 (en) | 2003-06-03 | 2005-01-21 | Shanghai Centre Of Research And Development Of New Drugs | A fusion protein suitable to be expressed high effectively and the production method thereof |
CA2531773A1 (en) | 2003-07-21 | 2005-02-17 | Transgene S.A. | Novel multifunctional cytokines |
GB0420634D0 (en) * | 2004-09-16 | 2004-10-20 | Glaxosmithkline Biolog Sa | Vaccines |
JP5108521B2 (ja) * | 2004-10-14 | 2012-12-26 | クルセル ホランド ベー ヴェー | マラリア初回免疫/追加免疫ワクチン |
JP2008536515A (ja) * | 2005-04-18 | 2008-09-11 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド | ワクチンの調製のためのb型肝炎ウイルス表面抗原の発現 |
GB0513421D0 (en) * | 2005-06-30 | 2005-08-03 | Glaxosmithkline Biolog Sa | Vaccines |
TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
GB0614254D0 (en) * | 2006-07-18 | 2006-08-30 | Smithkline Beecham Biolog | Vaccine |
MX2009000650A (es) | 2006-07-18 | 2009-07-02 | Secretary Of The Army The Unit | Vacunas para malaria. |
EP2491947A3 (de) | 2006-09-07 | 2012-10-17 | GlaxoSmithKline Biologicals S.A. | Impfstoff |
US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
EP2068918B1 (de) | 2006-09-26 | 2012-05-02 | Infectious Disease Research Institute | Impfstoffzusammensetzung mit einem synthetischen adjuvans |
CN101522218B (zh) | 2006-10-12 | 2012-09-26 | 葛兰素史密丝克莱恩生物有限公司 | 包含水包油乳液佐剂的疫苗 |
PL2086582T3 (pl) | 2006-10-12 | 2013-04-30 | Glaxosmithkline Biologicals Sa | Kompozycja zawierająca adiuwant w postaci emulsji typu olej w wodzie |
EA021391B1 (ru) | 2007-03-02 | 2015-06-30 | Глаксосмитклайн Байолоджикалс С.А. | Способ индукции иммунного ответа, вакцинная композиция, ее применение и набор |
US9717788B2 (en) | 2007-03-02 | 2017-08-01 | Glaxosmithkline Biologicals Sa | Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant |
AR066405A1 (es) | 2007-04-20 | 2009-08-19 | Glaxosmithkline Biolog Sa | Vacuna |
BRPI0815199A2 (pt) | 2007-08-13 | 2015-03-31 | Glaxosmithkline Biolog Sa | Uso de um antígeno derivado da proteína circunsporozóite de plasmodium falciparum |
WO2009080803A1 (en) * | 2007-12-24 | 2009-07-02 | Glaxosmithkline Biologicals S.A. | Vaccines for malaria |
GB0815872D0 (en) | 2008-09-01 | 2008-10-08 | Pasteur Institut | Novel method and compositions |
EP2437753B1 (de) | 2009-06-05 | 2016-08-31 | Infectious Disease Research Institute | Synthetische glucopyranosyl-lipid-adjuvanzien und impfstoffzusammensetzungen die diese enthalten |
US9555089B2 (en) | 2009-08-18 | 2017-01-31 | The Rockefeller University | Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes |
MX354752B (es) | 2010-09-27 | 2018-03-20 | Janssen Vaccines & Prevention Bv | Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria. |
GB201022007D0 (en) | 2010-12-24 | 2011-02-02 | Imp Innovations Ltd | DNA-sensor |
US9044420B2 (en) | 2011-04-08 | 2015-06-02 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
GB201116248D0 (en) | 2011-09-20 | 2011-11-02 | Glaxosmithkline Biolog Sa | Liposome production using isopropanol |
US11510875B2 (en) | 2012-02-07 | 2022-11-29 | Access To Advanced Health Institute | Adjuvant formulations comprising TLR4 agonists and methods of using the same |
CA2863695C (en) | 2012-02-16 | 2023-01-17 | Vlp Therapeutics, Llc | Virus like particle composition |
EP3388835B1 (de) | 2012-05-16 | 2020-04-01 | Immune Design Corp. | Impfstoffe gegen hsv-2 |
JP6430949B2 (ja) | 2012-10-23 | 2018-11-28 | エモリー ユニバーシティ | Gm−csfとil−4のコンジュゲート、組成物、ならびにそれに関連する方法 |
EP2940133A4 (de) | 2012-12-25 | 2016-07-06 | Chemo Sero Therapeut Res Inst | Impfstoff für hpv-infektion und/oder hepatitis b mit chimärem hpv/hbs-protein als wirkstoff |
WO2014107731A1 (en) | 2013-01-07 | 2014-07-10 | Biomedical Research Models, Inc. | Therapeutic vaccines for treating herpes simplex virus type 2 infections |
WO2014111733A1 (en) * | 2013-01-21 | 2014-07-24 | Isis Innovation Limited | Composition and uses thereof |
ES2924914T3 (es) | 2013-03-15 | 2022-10-11 | Glaxosmithkline Biologicals Sa | Vacuna contra rinovirus humano |
US8957047B2 (en) | 2013-04-18 | 2015-02-17 | Immune Design Corp. | GLA monotherapy for use in cancer treatment |
AP2015008926A0 (en) * | 2013-06-03 | 2015-12-31 | Vlp Therapeutics Llc | Malaria vaccine |
US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
TWI676636B (zh) | 2013-07-12 | 2019-11-11 | Vlp醫療股份有限公司 | 包含pd-1抗原或pd-1配體抗原的類病毒粒子 |
EP2873728A1 (de) | 2013-11-18 | 2015-05-20 | Institut Pasteur | Subunit-Impfstoff-Plattform auf Grundlage multimerer Ribonukleoproteine mit Nukleoproteinen eines nichtsegmentierten Negativstrang-RNA-Virus als Träger von heterologen Polypeptiden |
AU2014373928C1 (en) | 2013-12-31 | 2020-12-17 | Access To Advanced Health Institute | Single vial vaccine formulations |
US10385101B2 (en) | 2014-08-08 | 2019-08-20 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
TWI720946B (zh) | 2014-08-08 | 2021-03-11 | 美商Vlp醫療股份有限公司 | 包含改質套膜蛋白質e3之類病毒粒子 |
EP3685852A1 (de) | 2014-09-01 | 2020-07-29 | International Centre for Genetic Engineering and Biotechnology | Impfstoff |
EP3191589A4 (de) | 2014-09-11 | 2018-05-09 | VLP Therapeutics, LLC | Flavivirusähnliche partikel |
WO2016184784A1 (en) | 2015-05-15 | 2016-11-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Peptides including binding domain of plasmodium falciparum proteins (cbp1 and cbp2) to chemokine cx3cl1 |
WO2017176076A1 (en) | 2016-04-06 | 2017-10-12 | Ewha University - Industry Collaboration Foundation | A peptide with ability to penetrate cell membrane |
MX2018013640A (es) | 2016-05-16 | 2019-08-01 | Infectious Disease Res Inst | Liposomas pegiladas y metodos de uso. |
HUE059605T2 (hu) | 2016-05-16 | 2022-11-28 | Access To Advanced Health Inst | TLR agonista tartalmú készítmény és használati eljárások |
US11173126B2 (en) | 2016-06-01 | 2021-11-16 | Infectious Disease Research Institute | Nanoalum particles comprising a PAA sizing agent |
US10695424B2 (en) | 2016-12-07 | 2020-06-30 | Glaxosmithkline Biologicals S.A. | Method of making a liposome composition |
GB201621686D0 (en) | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
GB201707700D0 (en) | 2017-05-12 | 2017-06-28 | Glaxosmithkline Biologicals Sa | Dried composition |
IE20190084A3 (en) | 2017-05-30 | 2023-07-19 | Glaxosmithkline Biologicals Sa | Novel methods for manufacturing an adjuvant |
EP3638207A1 (de) | 2017-06-15 | 2020-04-22 | Infectious Disease Research Institute | Nanostrukturierte lipidträger sowie stabile emulsionen und ihre verwendung |
AU2018330165A1 (en) | 2017-09-08 | 2020-04-02 | Access To Advanced Health Institute | Liposomal formulations comprising saponin and methods of use |
EP3717001A1 (de) | 2017-12-01 | 2020-10-07 | GlaxoSmithKline Biologicals S.A. | Saponinreinigung |
CN113631573A (zh) | 2019-03-25 | 2021-11-09 | 国家医疗保健研究所 | 通过靶向新Tau物种治疗Tau蛋白病的方法 |
KR20220125149A (ko) | 2019-05-25 | 2022-09-14 | 액세스 투 어드밴스드 헬스 인스티튜트 | 애주번트 백신 에멀션을 분무 건조시키기 위한 조성물 및 방법 |
CA3142300A1 (en) | 2019-06-05 | 2020-12-10 | Glaxosmithkline Biologicals Sa | Saponin purification |
AU2021337493A1 (en) | 2020-09-04 | 2023-05-18 | Access To Advanced Health Institute | Co-lyophilized rna and nanostructured lipid carrier |
EP4355774A1 (de) | 2021-06-17 | 2024-04-24 | Atreca, Inc. | Anti-csp-antikörper |
EP4169513A1 (de) | 2021-10-19 | 2023-04-26 | GlaxoSmithKline Biologicals S.A. | Hilfsstoffzusammensetzung enthaltend sting agonisten |
WO2024052882A1 (en) | 2022-09-09 | 2024-03-14 | Access To Advanced Health Institute | Immunogenic vaccine composition incorporating a saponin |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4722840A (en) * | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
DE3584866D1 (de) * | 1984-09-12 | 1992-01-23 | Chiron Corp | Hybridpartikel-immunogene. |
AP56A (en) * | 1987-01-30 | 1989-09-26 | Smithkline Biologicals S A | Hepatitis B virus surface antigens and hybrid antigehs containing them. |
US4886782A (en) * | 1987-02-26 | 1989-12-12 | The United States Of America As Represented By The Department Of Health And Human Services | Malarial immunogen |
IL86833A0 (en) * | 1987-06-22 | 1988-11-30 | Medico Labs | Peptide containing immunogenic particles |
GB8812214D0 (en) * | 1988-05-24 | 1988-06-29 | Hoffmann La Roche | Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope |
US5028425A (en) * | 1988-07-07 | 1991-07-02 | The United States Of America As Represented By The Department Of Health And Human Services | Synthetic vaccine against P. falciparum malaria |
-
1992
- 1992-11-11 WO PCT/EP1992/002591 patent/WO1993010152A1/en active IP Right Grant
- 1992-11-11 AU AU29278/92A patent/AU2927892A/en not_active Abandoned
- 1992-11-11 KR KR1019940701652A patent/KR100251505B1/ko not_active IP Right Cessation
- 1992-11-11 SG SG1996009300A patent/SG48390A1/en unknown
- 1992-11-11 ES ES92923486T patent/ES2129461T3/es not_active Expired - Lifetime
- 1992-11-11 AT AT92923486T patent/ATE177755T1/de active
- 1992-11-11 DE DE69228698T patent/DE69228698T2/de not_active Expired - Lifetime
- 1992-11-11 JP JP50895793A patent/JP3954643B2/ja not_active Expired - Lifetime
- 1992-11-11 DK DK92923486T patent/DK0614465T3/da active
- 1992-11-11 EP EP92923486A patent/EP0614465B1/de not_active Expired - Lifetime
- 1992-11-11 CA CA002123612A patent/CA2123612C/en not_active Expired - Lifetime
- 1992-11-13 NZ NZ245114A patent/NZ245114A/en not_active IP Right Cessation
- 1992-11-13 MX MX9206574A patent/MX9206574A/es unknown
- 1992-11-13 PT PT101052A patent/PT101052B/pt not_active IP Right Cessation
-
1997
- 1997-02-14 AU AU14717/97A patent/AU712409B2/en not_active Expired
-
1998
- 1998-12-16 HK HK98113572A patent/HK1012405A1/xx not_active IP Right Cessation
-
1999
- 1999-03-18 GR GR990400668T patent/GR3029717T3/el unknown
-
2007
- 2007-03-15 JP JP2007066032A patent/JP4241846B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ES2129461T3 (es) | 1999-06-16 |
HK1012405A1 (en) | 1999-07-30 |
EP0614465B1 (de) | 1999-03-17 |
PT101052A (pt) | 1994-01-31 |
MX9206574A (es) | 1993-05-01 |
SG48390A1 (en) | 1998-04-17 |
WO1993010152A1 (en) | 1993-05-27 |
EP0614465A1 (de) | 1994-09-14 |
AU2927892A (en) | 1993-06-15 |
DE69228698D1 (de) | 1999-04-22 |
JP4241846B2 (ja) | 2009-03-18 |
ATE177755T1 (de) | 1999-04-15 |
DE69228698T2 (de) | 1999-09-16 |
GR3029717T3 (en) | 1999-06-30 |
JP3954643B2 (ja) | 2007-08-08 |
PT101052B (pt) | 1999-10-29 |
JP2007209343A (ja) | 2007-08-23 |
KR100251505B1 (ko) | 2000-05-01 |
JPH07501213A (ja) | 1995-02-09 |
NZ245114A (en) | 1995-07-26 |
CA2123612C (en) | 2002-06-25 |
AU1471797A (en) | 1997-06-12 |
CA2123612A1 (en) | 1993-05-27 |
AU712409B2 (en) | 1999-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0614465T3 (da) | Hybridprotein mellem CS fra Plasmodium og HBsAg | |
DK0835663T3 (da) | Kombinerede vacciner omfattende Hepatitis B overfladeantigen og andre antigener | |
ATE245164T1 (de) | Rekombinanter papillomavirus l1 | |
NL300336I1 (nl) | Vaccin tegen de bof dat een jeryl-lynn virusstam bevat | |
NZ219516A (en) | Fusion proteins of hbcag (hepatitis b virus core antigen) | |
KR890701743A (ko) | B형 간염 표면 항원 백신 | |
IL90134A0 (en) | Gene for encoding a human malaria vaccine antigen,malarial vaccines and pharmaceutical compositions | |
TR199501557A2 (tr) | PreS2 peptid iceren hepatiti b viral yüzey antijenini aritma prosesi. | |
EP0542753A4 (en) | Epitopes of the pre-s region of hepatitis b virus surface antigen | |
ZA888580B (en) | New immunologically active synthetic peptides useful for preparing an antimalarial vaccine | |
ATE177010T1 (de) | Immunverstärkung von impfstoffen, besonders von impfstoffen gegen schweinepleuropneumonie | |
DE9117146U1 (de) | Impfstoffe gegen virale Antigene | |
NO930883L (no) | Peptider for bruk ved vaksinasjon og induksjon av noeytraliserende antistoffer mot hiv | |
KR880701732A (ko) | 플라스모듐 팔시파룸(Plasmodium falciparum)의 분열체 표면 항원 | |
CS578887A1 (en) | Inactivated antigen of cattle's mucosal disease's virus | |
BR1100913A (pt) | Vacinas combinadas compreendendo o antìgeno superficial da hepatite b e outros antìgenos | |
ZA932210B (en) | A process for preparation of a recombinant hepatitis B surface antigen, and antigen and vaccine based thereon |